Maprotiline can directly bind to CRABP1 and inhibit its biological activity, which possibly suppress the phosphorylation of SREBP2 caused by ERK pathway activation and finally inhibit cholesterol biosynthesis and tumor growth. This evidence concerns the gene CRABP1 and neoplasm.